Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US

Study (n=506 on a PCSK9 inhibitor) noted over a 2-year period, only modest intensifications of lipid-lowering therapies were observed (17.1%), with only 1 in 3 patients achieving a LDL-cholesterol level less than 70 mg/Dl (1.81 mmol/L) at 2 years.

Source:

JAMA Cardiology